Promore Pharma
25.10.2021 09:21:54 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 25, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Stockholm 25 October 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announces that a peer-reviewed scientific article describing the results of a clinical study with ropocamptide for the treatment of venous leg ulcers has been published in the journal Wound Repair and Regeneration.
In 2020, Promore Pharma completed a clinical trial, HEAL LL-37, a phase IIb double-blind, randomized, placebo-controlled study aimed at evaluating the efficacy and safety of a new drug, LL-37 / ropocamptide for local administration in combination with compression therapy. The study was performed on 148 patients suffering from difficult-to-heal venous leg ulcers.
Today, the company announces that a scientific article has been published in the journal Wound Repair and Regeneration, which is the journal of the international society in wound care, Wound Healing Society. Co-authors of the article are several internationally renowned subject area experts, including professors Jan Apelqvist, Arkadiusz Jawien, and Folke Sjöberg.
" We are very content that the results of HEAL LL-37 are now published and available to the scientific community and the general public. The publication is a confirmation of the quality of the completed clinical study ", says Jonas Ekblom, CEO of Promore Pharma.
" Once again, we thank all the staff at the healthcare facilities who have participated in the study for their valuable contributions, " says Margit Mahlapuu, CSO of Promore Pharma.
The published article is entitled "Evaluation of LL-37 in Healing of Hard-to-Heal Venous Leg Ulcers: a Multicentric Prospective Randomized Placebo-Controlled Clinical Trial" and can be read in its entirety via the following link:
https://onlinelibrary.wiley.com/doi/full/10.1111/wrr.12977
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/669452/Promore-Pharma-Announces-that-Scientific-Article-has-Been-Published-on-Clinical-Study-Results-with-Ropocamptide-for-Venous-Leg-Ulcers
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 202630.6.2026 20:55:00 CEST | Press release
THUNDER BAY, ON / ACCESS Newswire / June 30, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the three-month period ended April 30, 2026, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at April 30, 2026 of $35,855,341 Total cash as at April 30, 2026 of $664,328 Working capital deficiency as at April 30, 2026 of $2,683,766 Shareholder's equity as at April 30, 2026 of $32,258,687 During the three-month period ended April 30, 2026, the Company incurred $57,783 in cost for exploration activities at the TBN project. During the quarter, the Company has been pursuing project financing alternatives while continuing to advance critical aspects of the project including progressing Advanced Exploration permitting discussions, and detailed planning for the next phase of exploration at E
Sauce Labs Becomes the First Dedicated Software Quality Platform to Achieve ISO 42001 Certification for Responsible AI30.6.2026 17:00:00 CEST | Press release
As AI takes on decisions that used to belong to engineers, the world's largest continuous testing cloud joins the small group of companies in any industry independently certified to govern AI responsibly SAN FRANCISCO, CA / ACCESS Newswire / June 30, 2026 / Sauce Labs, the world's largest continuous testing cloud, today announced it has achieved ISO/IEC 42001 certification, the first international standard for the responsible management of artificial intelligence. The certification covers Sauce AI, including Sauce AI for Insights and Sauce AI for Test Authoring, and makes Sauce Labs the first company dedicated to software quality to bring its AI capabilities under a fully certified AI Management System. Only a small number of companies worldwide, in any industry, have cleared this bar. Software is being written faster than at any point in history, and AI is now making quality decisions that used to belong to engineers. That shift has changed the question enterprise buyers ask. It is no
Human-Robot Collaboration Takes Center Stage at Prestigious Logistics Award30.6.2026 15:00:00 CEST | Press release
Denmark's The Mobile Robot Company wins IFOY Industrial Truck of the Year 2026 with a self-driving pallet jack built to empower warehouse operators rather than replace them. STUTTGART, DE / ACCESS Newswire / June 30, 2026 / In warehouses and factories, much of the work that keeps goods moving is still measured in footsteps. Operators walk the same routes, push the same loads, and repeat the same transport tasks hour after hour. For years, automation has promised to remove that work, but often with a catch: complex projects, fixed infrastructure, long integrations, and systems that assume people should be designed out of the process. At this year's IFOY AWARD, one of intralogistics' most respected technology prizes, the Industrial Truck of the Year award went to a different idea. The Mobile Robot Company, a young Danish robotics startup, won the 2026 title for the J1600 self-driving pallet jack, a robot designed not to replace the warehouse operator, but to work under the operator's dir
RAK ICC Launches New Business Centre in Ras Al Khaimah30.6.2026 14:00:00 CEST | Press release
New initiative creates a dedicated hub for private wealth advisors, family offices and international families in the UAE RAS AL KHAIMAH CITY, AE / ACCESS Newswire / June 30, 2026 / RAK International Corporate Centre (RAK ICC), one of the UAE's leading international corporate registries for private wealth and cross-border structuring, today announced the launch of its new Business Centre in Ras Al Khaimah - a new destination designed specifically for advisors, entrepreneurs, family offices and international families seeking a professional and lasting presence in the UAE. Officially opening on 1 July 2026, the Business Centre reflects RAK ICC's broader vision of creating a more connected and relationship-driven private wealth ecosystem within the emirate. Located within RAK ICC's headquarters, the centre offers convenient access to major transport and commercial hubs, situated approximately 45 minutes from Dubai International Airport and within proximity to Ras Al Khaimah's key business
Affiliate of Pacific Avenue Capital Partners Completes Acquisition of ESE World from Amcor30.6.2026 13:50:00 CEST | Press release
PARIS, FR / ACCESS Newswire / June 30, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a global private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has completed the acquisition of ESE World (the "Company" or "ESE") from Amcor, one of the world's leading packaging companies. ESE is Europe's leading manufacturer of waste and recycling container systems, serving municipalities and businesses globally. The Company produces mobile waste containers, collection banks, hazardous materials containers, and public furnishing solutions from three manufacturing facilities in Germany (Neuruppin and Olpe) and France (Crissey), generating approximately €300m in revenues. Having completed the carve-out from Amcor, ESE will operate as an independent company with the focus and resources to pursue its next phase of growth. Pacific Avenue will work in close partnership with the management te
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom